dc.contributor | Real World Data Working Group | |
dc.contributor.author | Vivanco-Hidalgo, Rosa Maria | |
dc.contributor.author | Molina, Israel | |
dc.contributor.author | Martinez, Elisenda | |
dc.contributor.author | Roman-Viñas, Ramón | |
dc.contributor.author | Sánchez-Montalvá, Adrián | |
dc.contributor.author | Fibla Palazón, Joan | |
dc.contributor.author | Pontes, Caridad | |
dc.contributor.author | Velasco Muñoz, César | |
dc.date.accessioned | 2021-04-07T10:06:52Z | |
dc.date.available | 2021-04-07T10:06:52Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1560-7917 | |
dc.identifier.issn | 1025-496X | |
dc.identifier.uri | http://hdl.handle.net/10459.1/70934 | |
dc.description.abstract | Background: Several clinical trials have assessed the protective potential of chloroquine and hydroxychloroquine. Chronic exposure to such drugs might lower the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or severe coronavirus disease (COVID-19). Aim: To assess COVID-19 incidence and risk of hospitalisation in a cohort of patients chronically taking chloroquine/hydroxychloroquine. Methods: We used linked health administration databases to follow a cohort of patients with chronic prescription of hydroxychloroquine/chloroquine and a control cohort matched by age, sex and primary care service area, between 1 January and 30 April 2020. COVID-19 cases were identified using International Classification of Diseases 10 codes. Results: We analysed a cohort of 6,746 patients (80% female) with active prescriptions for hydroxychloroquine/chloroquine, and 13,492 controls. During follow-up, there were 97 (1.4%) COVID-19 cases in the exposed cohort
and 183 (1.4%) among controls. The incidence rate was very similar between the two groups (12.05 vs 11.35 cases/100,000 person-days). The exposed cohort was not at lower risk of infection compared with controls (hazard ratio (HR): 1.08; 95% confidence interval (CI): 0.83–1.44; p=0.50). Forty cases (0.6%) were admitted to hospital in the exposed cohort and 50 (0.4%) in the control cohort, suggesting a higher hospitalisation rate in the former, though differences were not confirmed after adjustment (HR: 1·46; 95% CI: 0.91–2.34; p=0.10). Conclusions: Patients chronically exposed to chloroquine/hydroxychloroquine did not differ in risk of COVID-19 nor hospitalisation, compared with controls. As controls were mainly female, findings might not be generalisable to a male population. | ca_ES |
dc.language.iso | eng | ca_ES |
dc.publisher | European Centre for Disease Prevention and Control | ca_ES |
dc.relation.isformatof | Reproducció del document publicat a https://doi.org/10.2807/1560-7917.ES.2021.26.9.2001202 | ca_ES |
dc.relation.ispartof | Eurosurveillance, 2021, vol. 26, num. 9, p. 2001202 | ca_ES |
dc.rights | cc-by (c) Vivanco-Hidalgo et al., 2021 | ca_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.other | COVID-19 (Malaltia) | ca_ES |
dc.title | Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020 | ca_ES |
dc.type | info:eu-repo/semantics/article | ca_ES |
dc.identifier.idgrec | 031264 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | ca_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | ca_ES |
dc.identifier.doi | https://doi.org/10.2807/1560-7917.ES.2021.26.9.2001202 | |